TGFB1 and laryngotracheoesophageal cleft: Drugs that target TGF‐β1 have the potential to not only regulate the oncogenic activity of cells through PLTC but also reduce resistance to PD‐1/PD‐L1 immune therapy in patients with LC [39, 40], highlighting the significant value of these drugs in combating LC.